Navigation Links
XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
Date:10/16/2007

Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast

MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21

Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting

Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., Director of Cardiology, University Medical Center,

Utrecht, Netherlands, will present a historical overview and current

perspective on the treatment of multivessel coronary disease and the

treatment of long lesions. An overview of the Custom NX(R) DES System with

respect to the treatment of multivessel and diffuse disease will be

discussed, along with the one-year follow-up results of the CUSTOM II

Trial.

Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington

Convention Center

Event: Evening Symposium -- Delivering Safety to Today's Patients

Professor Eberhard Grube, M.D., Chief
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... (Nasdaq: SLTM ), a global leader in the ... the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton ... pm Pacific Time. Stephen J. Fanning, Chairman, President and Chief ... corporate events. Attendance at this conference is by ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) ... medical devices to biopharmaceutical and healthcare organizations and ... efficacy services in drug development, announced today results ...  Unless otherwise noted, all comparative numbers refer to ...
Cached Medicine Technology:Solta Medical to Present at the JMP Securities Research Conference 2ERT Reports First Quarter 2011 Operating Results 2ERT Reports First Quarter 2011 Operating Results 3ERT Reports First Quarter 2011 Operating Results 4ERT Reports First Quarter 2011 Operating Results 5ERT Reports First Quarter 2011 Operating Results 6ERT Reports First Quarter 2011 Operating Results 7ERT Reports First Quarter 2011 Operating Results 8ERT Reports First Quarter 2011 Operating Results 9ERT Reports First Quarter 2011 Operating Results 10ERT Reports First Quarter 2011 Operating Results 11
(Date:4/24/2014)... BrainHealth will bring together national experts to discuss ... its inaugural Brain Health Summit, titled "The Human ... include Dr. Sandra Bond Chapman, founder and chief ... Chuck Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) ... and Early Learning, U.S. Department of Education. The ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... CORVALLIS, Ore. An Oregon State University researcher has ... severity of the symptoms of autism spectrum disorder in ... the be the first to show a direct relationship ... of fine and gross motor skills should be included ... Megan MacDonald, an assistant professor in OSU,s College of ...
(Date:4/24/2014)... a scientist at the University of York reveals that ... development of the nervous system may also play a ... A research team, led by Dr Will Brackenbury, a ... at York, has studied how voltage-gated sodium channels assist ... found in the membranes of excitable cells, such as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... , , ... Corp., the leader in clinically proven brain fitness software, and ... collaboration to empower individuals with knowledge and tools that can ... this first-of-its-kind offer, consumers will have the opportunity to complement ...
... , , HOUSTON, Sept. ... that Dan Moore, President and Chief Executive Officer, and Greg Browne, ... Conference in New York on Tuesday, September 22, 2009 at 4:00 ... live and by replay at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=82_IT8KY1C . ...
... , PORTLAND, Maine, Sept. 10 ... Council for Disability Awareness (CDA) reveals a surge in the number ... , , The CDA,s 4(th) Annual Long-Term Disability ... identifies continuing and emerging disability trends among U.S. workers. Fifteen CDA ...
... STERIS Corporation (NYSE: STE ) today announced that the ... in New York on Tuesday, September 22, 2009. Michael J. ... p.m., Eastern time. , , The presentation can ... at www.steris-ir.com . The presentation will be ...
... ... Pioneer in the Development of Telehealth-Supported Solutions for Connected Care , ... Minneapolis, MN (PRWEB) September 10, 2009 ... Lenzmeier as chairman. Founded in 1993, ATI is the pioneer in the development and ...
... , , ANN ... biopharmaceutical company, today announced positive efficacy results from the second ... study for Ophena(TM) (ospemifene tablets), the company,s investigational ... (VVA). This study, together with the recent completion of ...
Cached Medicine News:Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 2Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 3Health News:Cyberonics to Present at UBS Global Life Sciences Conference 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 3Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 2Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 3Health News:Allen Lenzmeier Elected Chairman of the Board of Directors of American TeleCare, Inc. (ATI) 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 3Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: